BofA analyst Jason Gerberry lowered the firm’s price target on Relay Therapeutics to $25 from $27 and keeps a Buy rating on the shares. The Q4 print was “a relative non-event,” with the company reaffirming timelines for 2024 clinical data updates, says the analyst, who cites an updated net cash balance for the change in price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RLAY:
- Relay Therapeutics to Participate in Three Upcoming Investor Conferences
- Relay Therapeutics price target raised to $20 from $17 at H.C. Wainwright
- Relay Therapeutics reports Q 4 EPS (67c), consensus (75c)
- Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
- Relay Therapeutics price target raised to $30 from $25 at Stifel
